Safety and efficacy of tazarotene foam for the treatment of acne vulgaris

BACKGROUND: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. OBJECTIVE: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. METHODS: Five Phase I safety studies in normal controls are reviewed and tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Epstein, Erica L, Gold, Linda Stein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658431/
https://www.ncbi.nlm.nih.gov/pubmed/23696711
http://dx.doi.org/10.2147/CCID.S34054
_version_ 1782270273613987840
author Epstein, Erica L
Gold, Linda Stein
author_facet Epstein, Erica L
Gold, Linda Stein
author_sort Epstein, Erica L
collection PubMed
description BACKGROUND: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. OBJECTIVE: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. METHODS: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. CONCLUSION: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy.
format Online
Article
Text
id pubmed-3658431
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36584312013-05-21 Safety and efficacy of tazarotene foam for the treatment of acne vulgaris Epstein, Erica L Gold, Linda Stein Clin Cosmet Investig Dermatol Review BACKGROUND: Tazarotene foam is the first topical retinoid foam approved for the treatment of acne vulgaris. OBJECTIVE: To review the safety and efficacy studies of tazarotene foam in the treatment of moderate to severe acne. METHODS: Five Phase I safety studies in normal controls are reviewed and two Phase III safety and efficacy studies in patients with moderate to severe acne are reviewed. CONCLUSION: Tazarotene foam, 0.1% was effective in the treatment of moderate to severe acne vulgaris with an acceptable tolerability profile. This treatment provides a cosmetically favorable alternative for topical retinoid therapy. Dove Medical Press 2013-05-14 /pmc/articles/PMC3658431/ /pubmed/23696711 http://dx.doi.org/10.2147/CCID.S34054 Text en © 2013 Epstein and Gold, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Epstein, Erica L
Gold, Linda Stein
Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title_full Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title_fullStr Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title_full_unstemmed Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title_short Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
title_sort safety and efficacy of tazarotene foam for the treatment of acne vulgaris
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658431/
https://www.ncbi.nlm.nih.gov/pubmed/23696711
http://dx.doi.org/10.2147/CCID.S34054
work_keys_str_mv AT epsteinerical safetyandefficacyoftazarotenefoamforthetreatmentofacnevulgaris
AT goldlindastein safetyandefficacyoftazarotenefoamforthetreatmentofacnevulgaris

Ejemplares similares